Anna Mc Laughlin, Dr. rer.nat, Consultant. Pharmetheus
Cassian Yee, Professor, University of Texas MD Anderson Cancer Center
Cellular therapy, especially chimeric antigen receptor (CAR)-T cell therapy, has revolutionized the treatment of relapsed/refractory hematological malignancies. Several modeling and simulation (M&S) strategies, using a broad range of methodological approaches, have been developed to support both the rational development and clinical use of CAR-T cell therapy.
This session aims at reflecting on the potential of existing CAR-T cell M&S strategies and highlighting the requirements from different stakeholders (industry, clinical/research, and regulatory) to further establish their use. Finally, as cell therapies beyond CAR-T cells evolve rapidly for oncology and other therapeutic areas, this session aims to provide an outlook on emerging cell therapy concepts and the associated challenges in translating existing CAR-T cell M&S strategies to new therapeutic modalities.
Topics & speakers
Aman P. Singh, Ph.D.
Associate Director, Takeda
Loretta Nastoupil, MD, Associate Professor.
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center
Thibaud Derippe, Ph.D.
Clinical Pharmacologist & Pharmacometrician, AstraZeneca
Xiaofei Wang, Ph.D.